ALT5 Sigma (NASDAQ:ALTS) Shares Down 2.2% - What's Next?

Key Points

• Shares fell 2.2% to about $1.32 (day low $1.29) on Thursday with 1,152,010 shares traded, down roughly 43% from average, and the stock is trading below its 50‑day ($1.66) and 200‑day ($2.01) moving averages.
• Analyst sentiment is negative: Weiss Ratings reiterated a "Sell (D-)" and MarketBeat shows a consensus rating of "Sell" (one analyst).
• Recent quarterly results showed $0.29 EPS on $7.58 million revenue with a reported net margin of 133.06% and ROE of 8.6%, but liquidity appears weak (current and quick ratios of 0.79) while debt is minimal (debt/equity 0.01).

ALT5 Sigma Corporation (NASDAQ:ALTS - Get Free Report)'s share price traded down 2.2% during trading on Thursday . The company traded as low as $1.29 and last traded at $1.32. 1,152,010 shares traded hands during trading, a decline of 43% from the average session volume of 2,021,641 shares. The stock had previously closed at $1.35.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of ALT5 Sigma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of "Sell".

ALT5 Sigma Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 0.79 and a quick ratio of 0.79. The stock has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $2.01.

ALT5 Sigma (NASDAQ:ALTS - Get Free Report) last issued its quarterly earnings results on Monday, January 12th. The company reported $0.29 EPS for the quarter. The firm had revenue of $7.58 million for the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.

Institutional Investors Weigh In On ALT5 Sigma

Several institutional investors have recently added to or reduced their stakes in the business. Balyasny Asset Management L.P. purchased a new position in shares of ALT5 Sigma in the fourth quarter worth about $26,000. Arete Wealth Advisors LLC purchased a new stake in shares of ALT5 Sigma during the 3rd quarter valued at approximately $28,000. Profund Advisors LLC bought a new position in ALT5 Sigma in the 3rd quarter worth approximately $28,000. Victory Capital Management Inc. bought a new position in ALT5 Sigma in the 3rd quarter worth approximately $33,000. Finally, First Citizens Bank & Trust Co. purchased a new position in ALT5 Sigma in the 3rd quarter valued at approximately $35,000. 6.27% of the stock is owned by hedge funds and other institutional investors.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.